Kim Il-Jin, Kang Hio Chung, Jang Sang-Geun, Kim Kun, Ahn Sun-A, Yoon Hyun-Ju, Yoon Sang Nam, Park Jae-Gahb
Korean Hereditary Tumor Registry, Cancer Research Institute and Cancer Research Center, Seoul National University, Seoul, Korea.
Carcinogenesis. 2006 Mar;27(3):392-404. doi: 10.1093/carcin/bgi237. Epub 2005 Oct 11.
Various types of human cancers harbor BRAF somatic mutations, leading researchers to seek molecular targets for BRAF inhibitors. A mutually exclusive relationship has been observed between the BRAF-V600E mutation and K-ras mutations, suggesting that the BRAF-V600E mutation may differ from the other BRAF mutant types. Here, we used microarray analysis to examine differences between the BRAF and K-ras mutant colorectal samples and within the BRAF group (V600E versus non-V600E), in the hope that the identified gene sets could form the basis for new target development. Eleven colorectal cancers (CRCs) with BRAF mutations and nine with K-ras mutations were examined by high-density microarray analysis. We also tested whether other significant genetic or clinical status involved in CRC development, such as APC and TP53 mutations, MSI and TNM-Duke's staging, were related with the observed BRAF- or K-ras associated expression profiles. Unsupervised two-way hierarchical clustering and multidimensional scaling revealed that the differentially expressed genes clustered according to the mutation status of BRAF and K-ras, and that samples with the BRAF-V600E and non-V600E mutants could be distinguished from each other by gene profiling. Examination of TNM-Duke's staging, MSI and mutations in APC and TP53 revealed that these significant mutations could not account for the hierarchical clustering results observed in our study. We herein identified distinct gene expression patterns and gene sets that may form the basis for identification of BRAF-targeting molecules or provide researchers with a better understanding of the molecular pathogenesis underlying RAS-RAF signaling.
多种类型的人类癌症都存在BRAF体细胞突变,这促使研究人员寻找BRAF抑制剂的分子靶点。已观察到BRAF-V600E突变与K-ras突变之间存在相互排斥的关系,这表明BRAF-V600E突变可能与其他BRAF突变类型不同。在此,我们使用微阵列分析来检查BRAF和K-ras突变型结直肠癌样本之间以及BRAF组内(V600E与非V600E)的差异,希望所识别的基因集能够为新靶点的开发奠定基础。通过高密度微阵列分析检查了11例具有BRAF突变的结直肠癌(CRC)和9例具有K-ras突变的结直肠癌。我们还测试了CRC发生过程中涉及的其他重要遗传或临床状态,如APC和TP53突变、微卫星不稳定性(MSI)和TNM-杜克分期,是否与观察到的BRAF或K-ras相关表达谱有关。无监督双向分层聚类和多维标度分析表明,差异表达基因根据BRAF和K-ras的突变状态进行聚类,并且具有BRAF-V600E和非V600E突变体的样本可以通过基因谱分析相互区分。对TNM-杜克分期、MSI以及APC和TP53突变的检查表明,这些重要突变无法解释我们研究中观察到的分层聚类结果。我们在此识别出了不同的基因表达模式和基因集,这些可能为识别BRAF靶向分子奠定基础,或者为研究人员更好地理解RAS-RAF信号传导的分子发病机制提供帮助。